Management of Acute Stroke Patients on Treatment with New Oral Anticoagulants: Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Cerebral Infarction
    Ich
  • Age: Between 18 - 120 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Have been diagnosed with acute ischemic stroke and have been treated with dabigatran, rivaroxaban, apixaban, edoxaban within 7 days prior to admission, or
    2. Have been diagnosed with intracerebral hemorrhage and have been treated with warfarin or one of the new oral anticoagulants within 7 days prior to admission
    3. ARAMIS PRO follow-up study: Ability of patient or legally authorized representative to provide informed consent for longitudinal follow-up indicating they understand the purpose and the requirements of the study and are willing to participate.

You may not be eligible for this study if the following are true:

    1. Patients who were transferred from another hospital or discharged to other acute care facility will be excluded.

Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.